Q3001: Radioelements for brachytherapy, any type, each
Q3001 is a HCPCS Level II code for radioelements for brachytherapy, any type, each. It belongs to the Temporary Codes section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
Physician fee schedule statusC
Contractor-priced. Your MAC establishes the RVUs and the payment amount case by case, usually after reviewing documentation. There is no national amount to compute.
Global period: XXX
Want the dollar amount for your locality? The fee calculator applies your GPCI and the current conversion factor.
The CMS record for Q3001
- Long descriptor
- Radioelements for brachytherapy, any type, each
- Short descriptor
- Brachytherapy radioelements
- Added
- July 1, 2000
- BETOS
- P7A
- Pricing indicator
- 57: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Other carrier priced.
Codes adjacent to Q3001
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If Q3001 is not quite right, the correct code is very often within a few positions of it.
- Q2050Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg
- Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)
- Q2053Brexucabtagene autoleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2054Lisocabtagene maraleucel, up to 110 million autologous anti-cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2055Idecabtagene vicleucel, up to 510 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2056Ciltacabtagene autoleucel, up to 100 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2057Afamitresgene autoleucel, including leukapheresis and dose preparation procedures, per therapeutic dose
- Q2058Obecabtagene autoleucel, 10 up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per infusion
- Q3014Telehealth originating site facility fee
- Q3027Injection, interferon beta-1a, 1 mcg for intramuscular use
- Q3028Injection, interferon beta-1a, 1 mcg for subcutaneous use
- Q3031Collagen skin test
- Q4001Casting supplies, body cast adult, with or without head, plaster
- Q4002Cast supplies, body cast adult, with or without head, fiberglass
- Q4003Cast supplies, shoulder cast, adult (11 years +), plaster
- Q4004Cast supplies, shoulder cast, adult (11 years +), fiberglass